This project is aimed at advancing neuropsychological diagnostics, enriching and modernizing the panorama of both clinical and forensic psychometric testing. The rapid socio-demographic changes, the developments of neuropsychological semiotics and nosography, as well as the growing applicative specialization of neuropsychological assessment make it necessary to introduce further tools to satisfy the diagnostic requests in clinical contexts and more recently in the forensic field (i.e., tests to be administered remotely; bedside screeners; domain-specific in-depth tests; tools for assessing testamentary capacity). Specifically, the present study aims to: a) develop, calibrate and evaluate the psychometric properties of I and II level clinical and/or forensic neuropsychological tests evaluating instrumental and non-instrumental functions in a sample of neurologically healthy individuals representative of the Italian population ; b) evaluate the cross-sectional and longitudinal clinical usability of the aforementioned tests in clinical samples (patients with neurological and neuropsychiatric pathologies of different etiology).
Study Type
OBSERVATIONAL
Enrollment
300
Cognitive and behavioral tests and questionnaires
Istituto Auxologico Italiano IRCCS
Milan, Lombardy, Italy
RECRUITINGChange from baseline in Brief Assessment of Social Skills-Dementia (BASS-D)
A screening test of social cognition in neurodegeneration
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Picture Interpretation Test (PIT)
A test of executive functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Verbal Reasoning Test (VRT-A) - Absurdity sub-test
A test of verbal reasoning
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Brief Executive Language Screen (BELS)
A language test
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Bamberg Dementia Screening Test (BDST)
A test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Testament Definition Scale (TDS)
A scale to assess testament representation
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Testamentary Capacity Assessment Tool (TCAT)
A test to assess cognitive functions (i.e., memory, executive functions, social cognition, and numerical abilities) at the base of testamentary capacity
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone Interview for Cognitive Status (TICS)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Mini-Mental State Examination (I-TEL-MMSE)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Global Examination of Mental State (tele-GEMS)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Amyotrophic Lateral Sclerosis Cognitive Behavioural Screen (ALS-CBS™-PhV
A telephone-based screening test for cognitive functions in ALS
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Frontal Assessment Battery (t-FAB)
A telephone-based screening test of executive functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Development of the Bizzare Pictures Test (BPT)
A new visual test to assess reasoning abilities
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Development Telephone Language Screener (TLS)
A new telephone-based test to asses linguistic functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.